Google
Trusted Resources: News & Events
Latest announcements and gatherings
CIRM and NHLBI Collaborating to Fund Cell and Gene Therapies for Sickle Cell Disease
The California Institute for Regenerative Medicine (CIRM) and the National Heart, Lung and Blood Institute (NHLBI) have entered into a “landmark” collaboration to co-fund and help speed the development of cell and gene therapies to cure sickle cell disease (SCD), according to a press release.
The agreement was created under the National Institutes of Health’s “Cure Sickle Cell” initiative, led by NHLBI, the goal of which is to take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based therapies into clinical trials within five to 10 years.
This new collaboration will take advantage of CIRM’s vast resources and expertise, which have already resulted in more than 50 clinical trials in stem cell and regenerative medicine, and will provide lines of co-funding to CIRM-sponsored research.
“There is a real need for a new approach to treating SCD and making life easier for people with SCD and their families,” said Adrienne Shapiro, mother of a child with the disease and co-founder of Axis Advocacy.
+myBinderRelated Content
-
Shared Decision Making for Hydroxyurea Treatment Initiation in Children With Sickle Cell AnemiaClinical trials have demonstrated hydrox...
-
Phase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCDGlycoMimetics, in collaboration with Pfi...
-
Gene-Edited ‘Supercells’ Make Progress In Fight Against Sickle Cell DiseaseDoctors are reporting the first evidence...
-
Alabama Man Free of Sickle Cell After Gene Therapyhttps://www.youtube.com/watch?v=E9vYON8D...
-
NIH Launches new Collaboration to Develop Gene-Based Cures for Sickle Cell Disease and HIV on Global ScaleThe National Institutes of Health plans ...
-
Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased ...Treatment of vaso-occlusive crises (VOC)...
-
First Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.